CERS at a glance
CERUS CORP (CERS, SEC CIK 1020214) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding CERUS CORP (CERS) shares worth $188.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Jensen Chrystal on August 17, 2026 of 30,000 shares at $2.98 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $233.8M
- +16.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $188.7M · +0 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $64.018M, up $3.781M YoY, driven by platelet kits, IFC sales and EMEA LED illuminators
- Product gross margin 52% vs 53% YoY, pressured by foreign exchange, inventory costs and tariffs
- Product revenue $57.714M, up $5.016M, while government contract revenue fell $1.235M to $6.304M
- Cash, investments and restricted cash $57.734M vs $83.518M at December 31, 2025
- Near-term headwinds: tariffs, conflicts, supply-chain disruption and potential reductions or delays in BARDA funding
Risk Factors
- New regulatory risk: EU EUDAMED modules become mandatory May 28, 2026, increasing compliance costs
- BARDA funding risk: 2016 Agreement options discontinued, while 2024 Agreement potential funding increased to $209.0 million
- Regulatory approval risk: ANSM review continues for the red blood cell system’s MDR application after prior closure
- Market risk: U.S. platelet shortages may reduce demand for INTERCEPT-treated products despite safety-compliance options
- Customer concentration risk: American Red Cross represents the largest single portion of U.S. blood collection market
AI summary of the CERS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Cerus announced Q3 2026 financial results for the quarter ended September 30, 2026
- Detailed financial results and management commentary appear in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue $64.0M, up 6%, with product revenue $57.7M, up 10%, supporting continued commercial growth
- IFC demand surged approximately 80%, while U.S. IFC sales reached $5.6M versus $3.9M
Item EX-99.1: Item EX-99.1
- Q2 product revenue $57.4M, up 10% YoY; total revenue $63.3M, up 5%, despite government contract revenue declining 24%
- IFC demand increased approximately 20%; U.S. IFC sales reached $6.7M, up from $5.6M
Item 2.02: Results of Operations and Financial Condition
- Cerus announced second-quarter 2026 financial results for the period ended June 30, 2026
- Press release provides the substantive revenue, earnings, cash-flow and outlook details for investor review
Item 5.02: Departure/Appointment of Directors or Principal Officers
- William Greenman transitioned from CEO to Executive Chairman effective July 1, 2026, reducing his operating role while preserving board leadership
- Executive Chairman term runs through May 31, 2027, unless ended or extended earlier by agreement
AI summaries of CERS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CERS
Don't miss the next CERS filing
- Alerts as it files. A push when CERS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CERS, by share count.
- Ask anything. An AI agent that reads every CERS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Jensen Chrystal | Sell | Aug 17, 2026 | 30,000 | $2.98 |
| Jayaraman Vivek K | Sell | Jul 16, 2026 | 16,666 | $3.16 |
| Jayaraman Vivek K | A | Jul 1, 2026 | 369,686 | - |
| Jayaraman Vivek K | A | Jul 1, 2026 | 554,529 | - |
| Green Kevin Dennis | Sell | Jun 30, 2026 | 33,676 | $2.94 |
| Green Kevin Dennis | A | Jun 30, 2026 | 63,600 | - |
| Jayaraman Vivek K | Sell | Jun 30, 2026 | 42,359 | $2.94 |
| Jensen Chrystal | Sell | Jun 30, 2026 | 24,329 | $2.94 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $201.3M | $233.8M |
| Operating Income | - | -$14.2M | -$8.7M |
| Net Income | -$37.5M | -$20.9M | -$15.6M |
| Op. Margin | - | -7.1% | -3.7% |
| Net Margin | - | -10.4% | -6.7% |
| Balance Sheet | |||
| Total Assets | - | $200.9M | $221.9M |
| Equity | $52.6M | $56.1M | $64.2M |
| ROE | -71.2% | -37.3% | -24.3% |
| Per Share | |||
| EPS | - | $-0.11 | $-0.08 |
| Cash Flow | |||
| Operating CF | -$43.2M | $11.4M | $4.8M |
| CapEx | $4.6M | $2.8M | $3.7M |
Source: XBRL data in CERUS CORP (CERS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CERS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $188.7M |
| Q2 2026 | 27 | $234.7M |
| Q1 2026 | 26 | $135.1M |
| Q4 2025 | 25 | $155.3M |
| Q3 2025 | 25 | $121.5M |
| Q2 2025 | 25 | $106.7M |
| Q1 2025 | 26 | $80.7M |
| Q4 2024 | 21 | $73.8M |
- ARK Investment Management+2.58M (+14%)
- Vanguard Portfolio Management LLC+818.3K (+30%)
- State Street Corp+343.9K (+7%)
- Franklin Resources+331.4K (+37%)
- Goldman Sachs Group+233.4K (+10%)
- AQR Capital Management−1.07M (-57%)
- D.E. Shaw & Co−888.2K (-16%)
- Two Sigma Investments−741.4K (-21%)
- BlackRock−630.6K (-3%)
- Ameriprise Financial−374.3K (-32%)
- StoneX Group Inc.+12.5K
- FMR LLC (Fidelity)−1.41M
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CERS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
| 8-K | Jul 10, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
CERS SEC filings: frequently asked questions
Which institutions hold CERS stock?
As of September 30, 2026, the largest CERUS CORP (CERS) holders among the 13F filers tracked by SignalX were BlackRock ($51.4 million), ARK Investment Management ($48.8 million), Vanguard Capital Management LLC ($20.2 million), State Street Corp ($12.1 million), D.E. Shaw & Co ($10.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CERS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CERUS CORP (CERS) reported revenue of $233.8 million (up 16.1% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.
What did CERS report in its latest 8-K?
CERUS CORP (CERS) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Cerus announced Q3 2026 financial results for the quarter ended September 30, 2026.
What are the latest CERS SEC filings?
CERUS CORP (CERS) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on August 17, 2026.
What is CERS's SEC CIK number?
CERUS CORP (CERS)'s SEC Central Index Key (CIK) is 1020214. EDGAR lists every CERS filing under that number.
Ask anything about CERS
The research agent reads CERS's filings, financials, insider trades and 13F holders, then answers with sources.